ArticleCancer discovery2012
The promise of combining inhibition of PI3K and PARP as cancer therapy.
Article in Cancer discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge.Experimental & molecular medicine · 2026Review
- Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Oncogene · 2025Review
- Potential bidirectional regulatory effects of botanical drug metabolites on tumors and cardiovascular diseases based on the PI3K/Akt/mTOR pathway.Frontiers in pharmacology · 2025Review
- Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids.Scientific reports · 2024Article
- PARP inhibitors: enhancing efficacy through rational combinations.British journal of cancer · 2023Review
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.BMC cancer · 2023Article
- The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.Current oncology reports · 2022Review
- Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches.Molecular and cellular biochemistry · 2022Article
- Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.Pharmacogenomics and personalized medicine · 2021Review
- AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?Frontiers in pharmacology · 2021Review
- Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients withCancer discovery · 2020Article
- PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.Cancers · 2020Review
- PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Current oncology reports · 2020Review
- Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination.International journal of molecular sciences · 2019Article
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2019Review
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.The Lancet. Oncology · 2019Article
- Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.Nature communications · 2018Article
- Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Analyses of in vitro and patient-derived in vivo models of breast cancer reveal that a combination of inhibitors of the enzymes PARP and phosphoinositide 3-kinase (PI3K) is a potentially effective treatment regimen for breast cancer tumors with elevated activity of the PI3K pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.